Lactotripeptides and antihypertensive effects: a critical review
| Autor: | Joris Kloek, Esther Boelsma |
|---|---|
| Přispěvatelé: | TNO Kwaliteit van Leven |
| Rok vydání: | 2008 |
| Předmět: |
Male
Biomedical Research Unclassified drug Blood pressure regulation Drug bioavailability Cultured Milk Products Protein Conformation Dose time effect relation Medicine (miscellaneous) Hemodynamics Lactotripeptides Review Pharmacology chemistry.chemical_compound Absence of side effects Food intake Drug safety Clinical Trials as Topic Nutrition and Dietetics Middle Aged Milk Proteins Clinical trial Treatment Outcome Hypertension Systolic blood pressure Blood pressure antihypertensive agent Aortic pressure Cardiology Female Oligopeptides Lactotripeptide derivative Race difference Human Adult Drug megadose medicine.medical_specialty Ambulatory blood pressure Blood chemistry Antihypertensive effects Side effect Calcium antagonist Caucasian Placebo Drug Administration Schedule Treatment duration Antihypertensive therapy Low drug dose Drug potency Maximum blood pressure Milk peptides Diastolic blood pressure Internal medicine Dose response medicine Humans Antihypertensive Agents Antihypertensive activity business.industry Beta adrenergic receptor blocking agent Nonhuman Drug efficacy Health Nutrition chemistry Japanese Dipeptidyl carboxypeptidase inhibitor business |
| Zdroj: | British Journal of Nutrition, 6, 101, 776-786 |
| ISSN: | 1475-2662 0007-1145 |
| DOI: | 10.1017/s0007114508137722 |
| Popis: | Hypertension or high blood pressure is a significant health problem worldwide. Typically, lifestyle changes, including adopting a healthy diet, are recommended for people with an elevated blood pressure. Lactotripeptides are bioactive milk peptides with potential antihypertensive properties in man. These peptides, as part of a food product or as nutraceutical, may contribute to the prevention and treatment of hypertension. This paper reviews the current evidence of the blood pressure control properties of lactotripeptides in man. Blood pressure-lowering effects of lactotripeptides are typically measured after 4–6 weeks of treatment. However, in some cases, a blood pressure response has been observed after 1–2 weeks. Maximum blood pressure reductions approximate 13 mmHg (systolic blood pressure) and 8 mmHg (diastolic blood pressure) after active treatment compared with placebo, and are likely reached after 8–12 weeks of treatment. Effective dosages of lactotripeptides range from 3·07 to 52·5 mg/d. Evidence indicates that lactotripeptides are only effective at elevated blood pressure; no further lowering of normal blood pressure has been observed. Concomitant intake of antihypertensive medication does not seem to influence the potency of lactotripeptides to lower blood pressure. Similarly, ethnicity has not been found to influence the extent of lactotripeptide-induced blood pressure lowering. Based on the currently available data, lactotripeptides appear to be safe and effective. Thus, they can be part of a healthy diet and lifestyle to prevent or reduce high blood pressure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|